当前位置:首页 - 行情中心 - 鲁抗医药(600789) - 财务分析 - 现金流量表

鲁抗医药

(600789)

  

流通市值:88.43亿  总市值:88.43亿
流通股本:8.99亿   总股本:8.99亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,514,245,995.381,216,904,382.165,279,057,839.153,428,306,291.09
  收到的税费返还28,215,771.9416,545,683.2268,796,446.3870,459,425.84
  收到其他与经营活动有关的现金88,626,164.1747,165,370.81171,248,822.67287,264,460.39
  经营活动现金流入小计2,631,087,931.491,280,615,436.195,519,103,108.23,786,030,177.32
  购买商品、接受劳务支付的现金1,580,248,428.59887,950,268.433,492,970,042.752,195,345,697.22
  支付给职工以及为职工支付的现金349,428,640176,717,752.51739,896,813.83517,618,570.09
  支付的各项税费115,642,659.4435,462,359.78199,350,507.22164,112,898.01
  支付其他与经营活动有关的现金273,430,924.88153,613,861.81684,067,687.27504,238,754.2
  经营活动现金流出小计2,318,750,652.911,253,744,242.535,116,285,051.073,381,315,919.52
  经营活动产生的现金流量净额312,337,278.5826,871,193.66402,818,057.13404,714,257.8
二、投资活动产生的现金流量:
  处置固定资产、无形资产和其他长期资产收回的现金净额29,084,163.258,017.420,312,302.2420,153,581.09
  投资活动现金流入小计29,084,163.258,017.420,312,302.2420,153,581.09
  购建固定资产、无形资产和其他长期资产支付的现金134,413,489.7945,486,647.87279,181,894.96164,118,823.1
  支付其他与投资活动有关的现金-22,573,647.02-32,760,934.09
  投资活动现金流出小计134,413,489.7968,060,294.89279,181,894.96196,879,757.19
  投资活动产生的现金流量净额-105,329,326.59-68,002,277.49-258,869,592.72-176,726,176.1
三、筹资活动产生的现金流量:
  吸收投资收到的现金--17,355,157.7817,355,157.78
  取得借款收到的现金861,378,558.24601,000,0001,676,204,866.63904,000,000.03
  收到其他与筹资活动有关的现金--165,000,000.99-
  筹资活动现金流入小计861,378,558.24601,000,0001,858,560,025.4921,355,157.81
  偿还债务支付的现金872,111,459.73589,621,459.731,713,612,444.4959,810,129.61
  分配股利、利润或偿付利息支付的现金112,050,425.7315,381,975.76233,490,591.7149,846,940.61
  支付其他与筹资活动有关的现金--100,556,954.28-
  筹资活动现金流出小计984,161,885.46605,003,435.492,047,659,990.381,109,657,070.22
  筹资活动产生的现金流量净额-122,783,327.22-4,003,435.49-189,099,964.98-188,301,912.41
四、汇率变动对现金及现金等价物的影响5,177,073.161,019,984.4910,806,795.175,692,870.33
五、现金及现金等价物净增加额89,401,697.93-44,114,534.83-34,344,705.445,379,039.62
  加:期初现金及现金等价物余额495,701,191.97496,209,279.97530,045,897.37530,045,897.37
  期末现金及现金等价物余额585,102,889.9452,094,745.14495,701,191.97575,424,936.99
补充资料:
  净利润110,648,217.65-408,347,521.83-
  资产减值准备44,919,839.14-66,942,918.06-
  固定资产和投资性房地产折旧189,019,231.64-361,994,716.82-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧189,019,231.64-361,994,716.82-
  无形资产摊销23,289,598.57-39,609,462.13-
  长期待摊费用摊销207,786.3-405,233.53-
  处置固定资产、无形资产和其他长期资产的损失-54,688.61--153,424,695.55-
  固定资产报废损失329.76-41,910.93-
  公允价值变动损失71,340--29,520-
  财务费用26,072,458.63-67,810,528.28-
  投资损失2,083,662.72-7,590,617.17-
  递延所得税1,313,955.54-6,994,720.45-
  其中:递延所得税资产减少1,313,955.54-6,994,720.45-
  存货的减少171,901,889.75--145,062,874.28-
  经营性应收项目的减少-136,345,643.17--265,435,914.87-
  经营性应付项目的增加-140,485,944.07--7,355,398.71-
  其他632,542.63-688,693.45-
  现金的期末余额585,102,889.9-495,701,191.97-
  减:现金的期初余额495,701,191.97-530,045,897.37-
  现金及现金等价物的净增加额89,401,697.93--34,344,705.4-
公告日期2025-08-282025-04-302025-03-222024-10-30
审计意见(境内)标准无保留意见
TOP↑